Amgen's DeLLphi-305 win is incremental; structural price erosion still clouds Q3 setup

What happened

A Seeking Alpha article published on October 27 positions Amgen as a bargain ahead of its November 3 Q3 report, citing Q2 2026 non-GAAP EPS of $6.29 (up 25.8% sequentially) and positive DeLLphi-305 data for Imdelltra+Imfinzi in extensive-stage small cell lung cancer released on October 24. This bullish preview contrasts with DeepValue's latest master report, which rates AMGN a potential sell at approximately $339 per share because its 23.7x earnings and 19.4x EV/EBITDA multiples already discount sustained growth and obesity optionality from MariTide. The master report's fundamental concerns remain unresolved: ENBREL net price fell 38% year-over-year in Q3 2025, Otezla suffered a $1.2 billion impairment after IRA selection, and Prolia/XGEVA began facing biosimilar competition as RANKL patents expired in 2025. DeLLphi-305 is clinically encouraging but financially minor in the short term, as Imdelltra's contribution is small relative to Amgen's $36.8 billion 2025 revenue and extensive-stage SCLC is a limited indication. Therefore, a strong Q3 print would confirm execution but would not alter the structural price erosion, unresolved tax exposure, or MariTide Phase 3 uncertainty that leave little valuation cushion at current levels.

Implication

Near-term Q3 on November 3 may show continued biosimilar, Blincyto, and Repatha strength, but consensus already expects these contributions; only an upward revision to 2026 guidance or concrete MariTide progress would materially change the picture. DeLLphi-305 adds a potential line extension for Imdelltra/tarlatamab, yet ES-SCLC is a small indication and Imdelltra's current revenue contribution is unlikely to offset several billion dollars of legacy product decline from ENBREL/Otezla/Prolia over 2026-2027. The four structural pressures—IRA price cuts, biosimilar erosion, elevated net debt (~$48B, >4x net debt/EBITDA), and uncertain tax settlements—remain fully intact and are not addressed by the oncology data. Until MariTide Phase 3 readouts arrive, AMGN's premium valuation offers no margin of safety for execution misses in Horizon assets or faster-than-modeled legacy erosion. Therefore, maintain a defensive posture: trim into strength above $370, use $295 as the level where downside risk is better compensated, and reassess only if guidance is raised without deteriorating margins or if MariTide data significantly de-risk the obesity franchise.

Thesis delta

No material change to the potential-sell thesis. DeLLphi-305 is a positive but incremental oncology data point that does not shift the valuation calculus or mitigate the legacy franchise and tax/leverage risks highlighted in the master report. The market continues to price Amgen for flawless execution, and the article's 'bargain' framing ignores that most of the near-term upside is already reflected; risk-reward remains skewed negative above $330.